68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI

Ingo Janssen; Clara C Chen; David Taieb; Nicholas J Patronas; Corina M Millo; Karen T Adams; Joan Nambuba; Peter Herscovitch; Samira M Sadowski; Antonio T Fojo; Inga Buchmann; Electron Kebebew; Karel Pacak

doi:10.2967/jnumed.115.161018

68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI

Ingo Janssen, Clara C Chen, David Taieb, Nicholas J Patronas, Corina M Millo, Karen T Adams, Joan Nambuba, Peter Herscovitch, Samira M Sadowski, Antonio T Fojo, Inga Buchmann, Electron Kebebew, Karel Pacak

Clinic of Radiology and Nuclear Medicine

Abstract

UNLABELLED: Pheochromocytomas/paragangliomas overexpress somatostatin receptors, and recent studies have already shown excellent results in the localization of sympathetic succinate dehydrogenase complex, subunit B, mutation-related metastatic pheochromocytomas/paragangliomas using (68)Ga-DOTATATE PET/CT. Therefore, the goal of our study was to assess the clinical utility of this functional imaging modality in parasympathetic head and neck paragangliomas (HNPGLs) compared with anatomic imaging with CT/MRI and other functional imaging modalities, including (18)F-fluorohydroyphenylalanine ((18)F-FDOPA) PET/CT, currently the gold standard in the functional imaging of HNPGLs.

METHODS: (68)Ga-DOTATATE PET/CT was prospectively performed in 20 patients with HNPGLs. All patients also underwent (18)F-FDOPA PET/CT, (18)F-FDG PET/CT, and CT/MRI, with 18 patients also undergoing (18)F-fluorodopamine ((18)F-FDA) PET/CT. (18)F-FDOPA PET/CT and CT/MRI served as the imaging comparators.

RESULTS: Thirty-eight lesions in 20 patients were detected, with (18)F-FDOPA PET/CT identifying 37 of 38 and CT/MRI identifying 23 of 38 lesions (P < 0.01). All 38 and an additional 7 lesions (P = 0.016) were detected on (68)Ga-DOTATATE PET/CT. Significantly fewer lesions were identified by (18)F-FDG PET/CT (24/38, P < 0.01) and (18)F-FDA PET/CT (10/34, P < 0.01).

CONCLUSION: (68)Ga-DOTATATE PET/CT identified more lesions than other imaging modalities. With the results of the present study, and the increasing availability and use of DOTA analogs in the therapy of neuroendocrine tumors, we expect that (68)Ga-DOTATATE PET/CT will become the preferred functional imaging modality for HNPGLs in the near future.

Original language	English
Journal	Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Volume	57
Issue number	2
Pages (from-to)	186-91
Number of pages	6
ISSN	0161-5505
DOIs	https://doi.org/10.2967/jnumed.115.161018
Publication status	Published - 02.2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2967/jnumed.115.161018

Cite this

Janssen, I., Chen, C. C., Taieb, D., Patronas, N. J., Millo, C. M., Adams, K. T., Nambuba, J., Herscovitch, P., Sadowski, S. M., Fojo, A. T., Buchmann, I., Kebebew, E., & Pacak, K. (2016). 68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 57(2), 186-91. https://doi.org/10.2967/jnumed.115.161018

@article{ba421c7af5614748a86df1781c29ad71,

title = "68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI",

abstract = "UNLABELLED: Pheochromocytomas/paragangliomas overexpress somatostatin receptors, and recent studies have already shown excellent results in the localization of sympathetic succinate dehydrogenase complex, subunit B, mutation-related metastatic pheochromocytomas/paragangliomas using (68)Ga-DOTATATE PET/CT. Therefore, the goal of our study was to assess the clinical utility of this functional imaging modality in parasympathetic head and neck paragangliomas (HNPGLs) compared with anatomic imaging with CT/MRI and other functional imaging modalities, including (18)F-fluorohydroyphenylalanine ((18)F-FDOPA) PET/CT, currently the gold standard in the functional imaging of HNPGLs.METHODS: (68)Ga-DOTATATE PET/CT was prospectively performed in 20 patients with HNPGLs. All patients also underwent (18)F-FDOPA PET/CT, (18)F-FDG PET/CT, and CT/MRI, with 18 patients also undergoing (18)F-fluorodopamine ((18)F-FDA) PET/CT. (18)F-FDOPA PET/CT and CT/MRI served as the imaging comparators.RESULTS: Thirty-eight lesions in 20 patients were detected, with (18)F-FDOPA PET/CT identifying 37 of 38 and CT/MRI identifying 23 of 38 lesions (P < 0.01). All 38 and an additional 7 lesions (P = 0.016) were detected on (68)Ga-DOTATATE PET/CT. Significantly fewer lesions were identified by (18)F-FDG PET/CT (24/38, P < 0.01) and (18)F-FDA PET/CT (10/34, P < 0.01).CONCLUSION: (68)Ga-DOTATATE PET/CT identified more lesions than other imaging modalities. With the results of the present study, and the increasing availability and use of DOTA analogs in the therapy of neuroendocrine tumors, we expect that (68)Ga-DOTATATE PET/CT will become the preferred functional imaging modality for HNPGLs in the near future.",

author = "Ingo Janssen and Chen, {Clara C} and David Taieb and Patronas, {Nicholas J} and Millo, {Corina M} and Adams, {Karen T} and Joan Nambuba and Peter Herscovitch and Sadowski, {Samira M} and Fojo, {Antonio T} and Inga Buchmann and Electron Kebebew and Karel Pacak",

note = "{\textcopyright} 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.",

year = "2016",

month = feb,

doi = "10.2967/jnumed.115.161018",

language = "English",

volume = "57",

pages = "186--91",

journal = "Journal of nuclear medicine : official publication, Society of Nuclear Medicine",

issn = "0161-5505",

number = "2",

}

Janssen, I, Chen, CC, Taieb, D, Patronas, NJ, Millo, CM, Adams, KT, Nambuba, J, Herscovitch, P, Sadowski, SM, Fojo, AT, Buchmann, I, Kebebew, E & Pacak, K 2016, '68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 57, no. 2, pp. 186-91. https://doi.org/10.2967/jnumed.115.161018

68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. / Janssen, Ingo; Chen, Clara C; Taieb, David et al.
In: Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Vol. 57, No. 2, 02.2016, p. 186-91.

Research output: Journal Articles › Journal articles › Research › peer-review

TY - JOUR

T1 - 68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI

AU - Janssen, Ingo

AU - Chen, Clara C

AU - Taieb, David

AU - Patronas, Nicholas J

AU - Millo, Corina M

AU - Adams, Karen T

AU - Nambuba, Joan

AU - Herscovitch, Peter

AU - Sadowski, Samira M

AU - Fojo, Antonio T

AU - Buchmann, Inga

AU - Kebebew, Electron

AU - Pacak, Karel

PY - 2016/2

Y1 - 2016/2

N2 - UNLABELLED: Pheochromocytomas/paragangliomas overexpress somatostatin receptors, and recent studies have already shown excellent results in the localization of sympathetic succinate dehydrogenase complex, subunit B, mutation-related metastatic pheochromocytomas/paragangliomas using (68)Ga-DOTATATE PET/CT. Therefore, the goal of our study was to assess the clinical utility of this functional imaging modality in parasympathetic head and neck paragangliomas (HNPGLs) compared with anatomic imaging with CT/MRI and other functional imaging modalities, including (18)F-fluorohydroyphenylalanine ((18)F-FDOPA) PET/CT, currently the gold standard in the functional imaging of HNPGLs.METHODS: (68)Ga-DOTATATE PET/CT was prospectively performed in 20 patients with HNPGLs. All patients also underwent (18)F-FDOPA PET/CT, (18)F-FDG PET/CT, and CT/MRI, with 18 patients also undergoing (18)F-fluorodopamine ((18)F-FDA) PET/CT. (18)F-FDOPA PET/CT and CT/MRI served as the imaging comparators.RESULTS: Thirty-eight lesions in 20 patients were detected, with (18)F-FDOPA PET/CT identifying 37 of 38 and CT/MRI identifying 23 of 38 lesions (P < 0.01). All 38 and an additional 7 lesions (P = 0.016) were detected on (68)Ga-DOTATATE PET/CT. Significantly fewer lesions were identified by (18)F-FDG PET/CT (24/38, P < 0.01) and (18)F-FDA PET/CT (10/34, P < 0.01).CONCLUSION: (68)Ga-DOTATATE PET/CT identified more lesions than other imaging modalities. With the results of the present study, and the increasing availability and use of DOTA analogs in the therapy of neuroendocrine tumors, we expect that (68)Ga-DOTATATE PET/CT will become the preferred functional imaging modality for HNPGLs in the near future.

AB - UNLABELLED: Pheochromocytomas/paragangliomas overexpress somatostatin receptors, and recent studies have already shown excellent results in the localization of sympathetic succinate dehydrogenase complex, subunit B, mutation-related metastatic pheochromocytomas/paragangliomas using (68)Ga-DOTATATE PET/CT. Therefore, the goal of our study was to assess the clinical utility of this functional imaging modality in parasympathetic head and neck paragangliomas (HNPGLs) compared with anatomic imaging with CT/MRI and other functional imaging modalities, including (18)F-fluorohydroyphenylalanine ((18)F-FDOPA) PET/CT, currently the gold standard in the functional imaging of HNPGLs.METHODS: (68)Ga-DOTATATE PET/CT was prospectively performed in 20 patients with HNPGLs. All patients also underwent (18)F-FDOPA PET/CT, (18)F-FDG PET/CT, and CT/MRI, with 18 patients also undergoing (18)F-fluorodopamine ((18)F-FDA) PET/CT. (18)F-FDOPA PET/CT and CT/MRI served as the imaging comparators.RESULTS: Thirty-eight lesions in 20 patients were detected, with (18)F-FDOPA PET/CT identifying 37 of 38 and CT/MRI identifying 23 of 38 lesions (P < 0.01). All 38 and an additional 7 lesions (P = 0.016) were detected on (68)Ga-DOTATATE PET/CT. Significantly fewer lesions were identified by (18)F-FDG PET/CT (24/38, P < 0.01) and (18)F-FDA PET/CT (10/34, P < 0.01).CONCLUSION: (68)Ga-DOTATATE PET/CT identified more lesions than other imaging modalities. With the results of the present study, and the increasing availability and use of DOTA analogs in the therapy of neuroendocrine tumors, we expect that (68)Ga-DOTATATE PET/CT will become the preferred functional imaging modality for HNPGLs in the near future.

U2 - 10.2967/jnumed.115.161018

DO - 10.2967/jnumed.115.161018

M3 - Journal articles

C2 - 26564322

SN - 0161-5505

VL - 57

SP - 186

EP - 191

JO - Journal of nuclear medicine : official publication, Society of Nuclear Medicine

JF - Journal of nuclear medicine : official publication, Society of Nuclear Medicine

IS - 2

ER -

68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this